secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001746473-23-000029
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics Q1 net loss $37.5M; cash $577M; positive IPF 24-wk data
---------------------------------------------------------------------------

- Q1 net loss $37.5M vs $28.1M YoY; R&D expense $29.3M, G&A $14.2M.
- Cash and short-term investments $577.3M, expected to fund operations into H2 2026.
- INTEGRIS-IPF 320 mg 24-week data: bexotegrast well-tolerated with durable FVC, QLF, and cough improvements.
- Key 2023 milestones: INTEGRIS-PSC 12-wk data Q3; BEACON-IPF Ph2b start mid-2023; Ph1 oncology trial start Q2.
- Closed Jan 2023 public offering raising $269.9M net proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000174647323000029/0001746473-23-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000174647323000029/plrx-20230509.htm
  HTML page:      https://secwatch.observer/filing/0001746473-23-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer